TB-500 (Thymosin β4 fragment)

TB-500 vs Thymosin Beta-4

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

TB-500 is a seven-residue acetylated peptide at 889.0 Da. Thymosin beta-4 is the 43-residue parent protein at 4,963 Da. They share the LKKTETQ motif, but much of the frequently cited wound-repair and cardiac literature used the full protein rather than the fragment.

Key facts

TB-500
7 residues, 889.0 Da
Thymosin beta-4
43 residues, 4,963 Da
Shared
The LKKTETQ actin-binding motif
Motif position
Residues 17-23 of Tβ4
Actin work
Applies to the motif
Repair and cardiac work
Largely used the full protein

The structural relationship

Thymosin beta-4's actin-binding activity concentrates in a short internal sequence, LKKTETQ, occupying residues 17 to 23. TB-500 is that sequence synthesised alone with an acetylated N-terminus. It is a fragment in the literal sense (a piece of the parent), and it retains the motif most directly associated with actin binding.

Why a fragment is not a small version of the protein

The other 36 residues are not padding. Thymosin beta-4 has reported activities beyond actin sequestration, and a protein's behaviour depends on its whole structure: how it folds, what surfaces it presents, what else it can contact. Isolating one functional motif keeps the activity attributable to that motif and discards everything attributable to the rest. Assuming the fragment reproduces the protein is an assumption, not a deduction.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

Which literature applies to which

This is the practically important part. Actin-sequestration work is about the motif and transfers reasonably. The corneal wound-healing work reported by Sosne and colleagues, and the cardiac repair literature, largely used full-length thymosin beta-4. Citing that work as evidence about TB-500 the heptapeptide extends it beyond the molecule it was generated with.

Why the fragment is what is usually sold

Cost and difficulty. Seven residues is a routine solid-phase synthesis; 43 residues is a substantially harder one with more opportunity for deletion sequences and a higher price. The market settled on the fragment for practical reasons, and the name TB-500 followed it, while the literature people cite largely did not.

How to keep them straight

Ask what a study administered, not what the compound is called. Papers state the molecule they used. Where a paper used full-length thymosin beta-4 and a claim is being made about TB-500, the gap between them is a real one and worth noticing.

Quick reference

TB-500Thymosin beta-4
Residues743
Molecular weight889.0 Da4,963 Da
PubChem CID6270766216132341
CAS-77591-33-4
Contains LKKTETQYes, it is the whole moleculeYes (residues 17-23)
SynthesisRoutineSubstantially harder

Frequently asked questions

Does TB-500 do everything thymosin beta-4 does?

Not established. It retains the actin-binding motif; the parent has reported activities beyond that, and the other 36 residues are not inert filler.

Which was used in the wound-healing studies?

Largely full-length thymosin beta-4, including the corneal work. That is a meaningful distinction when the findings are cited for the fragment.

Why is the fragment sold instead of the protein?

Seven residues is a routine synthesis; 43 is much harder and more expensive, with more scope for deletion sequences.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More TB-500 (Thymosin β4 fragment) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.